Welcome to our dedicated page for ORGENESIS news (Ticker: ORGS), a resource for investors and traders seeking the latest updates and insights on ORGENESIS stock.
Orgenesis Inc. (NASDAQ: ORGS) is a pioneering biotech company focused on unlocking the potential of cell and gene therapies (CGTs). Headquartered in White Plains, New York, Orgenesis specializes in autologous therapies, employing a closed and automated processing system designed for compliant production close to the patient, enhancing the efficiency of treatments at the point of care (POCare).
The company operates through two main segments: Octomera and Therapies. Octomera is the company's decentralized cell therapy platform, which has been fundamental in their approach to CGT production. Their decentralized model allows for the integration of academia, hospitals, and industry partners to expedite the commercialization of these therapies. This approach not only reduces costs but also improves patient outcomes by bringing processing services closer to the patient.
Despite industry challenges in 2023, Orgenesis remains steadfast in its mission. CEO Vered Caplan highlighted the growing demand for decentralized cell therapy solutions due to cost pressures and patient demand. Orgenesis has seen support from regulators like the FDA and EMEA, who are progressing guidelines for decentralized production. These advancements have solidified the company’s strategic advantage in handling the development and regulatory processes of their products.
On the financial front, Orgenesis has made significant strides. The recent appointment of Victor Miller as CFO has brought renewed focus on their financial strategy, leveraging their robust cell processing expertise to secure their position in the life sciences sector. Their collaboration with Metalmark has provided critical support, aiding in navigating the biotech industry's fluctuations.
Orgenesis is also at the forefront of developing therapeutic exosomes through their EXOFASTTRACK project. This project aims to accelerate the clinical evaluation of therapeutic exosomes, providing a scalable and cost-effective production process that can revolutionize the field of advanced therapy medicinal products (ATMPs).
Furthermore, Orgenesis has strengthened its infrastructure through a strategic partnership with Germfree. This collaboration focuses on advancing Orgenesis’ therapeutic programs and cell processing services, aiming to make CGTs more accessible and affordable globally. The partnership also includes marketing Orgenesis' decentralized Octomera service platform and its Mobile Processing Units and Labs (OMPULs™).
Orgenesis continues to innovate and expand its global footprint, committed to bringing life-saving therapies to market faster and more efficiently. Their decentralized approach and strategic collaborations position them as leaders in transforming how cell and gene therapies are developed and delivered.
For more information, please visit www.orgenesis.com.
Orgenesis (NASDAQ: ORGS), a global biotech company focused on cell and gene therapies, announced CEO Vered Caplan's participation in a keynote series at the INTERPHEX conference in New York from April 25-27, 2023. Caplan will discuss innovations from the Company’s POCare Services subsidiary, including Orgenesis Mobile Processing Units and Labs (OMPULs), which aim to provide cost-effective, decentralized therapies at the point of care. This event showcases advancements in the pharmaceutical lifecycle and highlights regulatory support for continuous manufacturing in the biopharma industry. Orgenesis seeks to enhance the accessibility and affordability of cell and gene therapies globally through its innovative POCare Platform.
Orgenesis Inc. (NASDAQ: ORGS) announced a substantial revenue growth of 98% in Q4 2022, amounting to $13.6 million compared to $6.9 million in Q4 2021. The company's operating loss significantly decreased by 91%, demonstrating the effectiveness of its cost-efficient business model. Key advancements included signing a non-binding MOU with UC Davis for the deployment of Orgenesis Mobile Processing Units and Labs (OMPULs) and facilitating positive cash flow through its subsidiary Koligo Therapeutics. The company continues to expand its POCare therapeutic pipeline and leverage partnerships for growth. A conference call to discuss these developments is scheduled for today at 11:00 AM ET.
Orgenesis Inc. (NASDAQ: ORGS), a global biotech firm, will host a conference call on March 21, 2023, at 11:00 AM ET to discuss its corporate progress and developments. Interested participants can dial in or join via webcast on the company’s website. A replay will be available for one year post-event. Orgenesis focuses on optimizing cell and gene therapies, utilizing its POCare Platform to provide accessible treatments globally. The company emphasizes innovation in treatment development and delivery, targeting large patient populations through a collaborative network.
Orgenesis (NASDAQ: ORGS) has signed a non-binding memorandum of understanding (MOU) with UC Davis to deploy its proprietary Orgenesis Mobile Processing Units and Labs™ (OMPULs™) across California. The partnership aims to create a decentralized model for the development and manufacture of cell and gene therapies at point-of-care facilities in the state. The first stage focuses on establishing an OMPUL at UC Davis within 12 months of a definitive agreement. This collaboration is expected to lower costs and improve accessibility to these therapies for patients.
Orgenesis, Inc. (Nasdaq: ORGS) has completed a Registered Direct Offering, raising approximately $3.7 million by issuing 1,947,368 common shares and warrants at a price of $1.90 per share. Each warrant allows the purchase of an additional common share at the same exercise price and expires in five years. The proceeds will be used for general corporate purposes, including working capital and administrative expenses. Joseph Gunnar & Co., LLC served as the placement agent. This offering is registered under an effective shelf registration statement with the SEC.
Orgenesis (Nasdaq: ORGS) has entered into a securities purchase agreement with institutional investors to sell 1,947,368 shares of common stock and warrants to purchase up to 973,684 shares at a price of $1.90 per share. The gross proceeds are estimated to be around $3.7 million before expenses. The warrants are exercisable at the same price and will expire five years after issuance. The funds from this offering are intended for working capital and general corporate purposes. The transaction is expected to close around February 27, 2023, contingent on customary conditions.
FAQ
What is the current stock price of ORGENESIS (ORGS)?
What is the market cap of ORGENESIS (ORGS)?
What is Orgenesis Inc.'s primary focus?
Where is Orgenesis Inc. headquartered?
What are the main business segments of Orgenesis Inc.?
What is the Octomera platform?
Who is the CEO of Orgenesis Inc.?
What strategic partnership did Orgenesis recently announce?
How does Orgenesis contribute to the development of therapeutic exosomes?
What is the significance of Orgenesis' decentralized approach?
How has Orgenesis addressed the challenges in the biotech industry?
Where can I find more information about Orgenesis?
